Quidel Corporation., San Diego, California, has been awarded a maximum $710,570,885 indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with Sept. 14, 2022, ordering period end date. The primary customer is the Department of Health and Human Services. The type of appropriation is fiscal 2021 through 2022 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-21-D-0050). (Awarded Sept. 14, 2021)

Is it the flu or are you pregnant? Quidel Corporation can tell you quickly enough. The company makes rapid diagnostic in vitro test products used at the point-of-care (POC), usually at a doctor’s office or another outpatient setting. The diagnostic solutions aid in the detection and diagnosis of many critical diseases and other medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health, and thyroid diseases. Its cardiac immunoassay tests are used in physician offices, hospital laboratories and emergency departments, and other urgent care or alternative site settings. The majority of its revenue comes from its domestic operation. (www.dnb.com)